BioSpace News Archive

The rising number of pet owners across the world has driven the demand from a widespread network of industries catering to various demands of pet animals.

There are players operating in the global medical imaging information system market, for example, Varian Medical Systems, Hitachi, Mindray Medical, Toshiba, Siemens Healthcare, GE Healthcare, Fujifilm, Philips, Hologic, Neusoft Medical Systems, and Esaote.

Genentech, a member of the Roche Group, announced new data for Evrysdi® in spinal muscular atrophy.

Ipsen announced it will invest in a new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot, to deliver further innovation in the class with the aim of improving administration and the injection experience for patients.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept for its Chimeric Bait Receptor platform technology.

EdiGene, Inc. entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital for intellectual property related to methods and compositions for increasing fetal hemoglobin levels by disrupting BCL11A expression at the genomic level to treat hemoglobinopathies.

Prothena Corporation plc presented new preclinical data from both its dual Aβ/tau vaccine for the potential treatment and prevention of Alzheimer’s disease and from its tandem C-terminal α-synuclein vaccine programs for the potential treatment and prevention of Parkinson’s disease and related synucleinopathies.

Boston Scientific Corporation announced that, pursuant to the previously announced cash tender offer for up to $2.5 billion aggregate principal amount of the outstanding senior notes identified in the table and the related notes below, $5,139,194,000 in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Time, on March 15, 2022.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has signed a 5-year distribution agreement with Harrington Consultants Limited and its joint venture partner Al Mufid Pharmaceuticals.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in March.